Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.

The entities involved

• Daiichi Sankyo →

  Japanese pharmaceutical company

  • A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.Sun 09:52
  • The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Sun 09:52
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
• Pfizer →

  American multinational pharmaceutical and biotechnology corporation

  • Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22

Related events

• FDA granted accelerated approval for Etcamah combination therapy after trial results were presented at ASCO.Sep 4